On August 9 2023, CATALYST PHARMACEUTICALS ($NASDAQ:CPRX) announced their financial results for the second quarter of the fiscal year 2023, which ended on June 30 2023. The total revenue of the company for Q2 was USD 99.6 million, an increase of 87.5% compared to the same quarter the previous year. Net income also rose to USD 37.8 million, up 74.7% from the same period in the prior year.
CATALYST PHARMACEUTICALS reported financial results for the Q2 ending August 9, 2023 on Wednesday. The stock opened at $14.3 and closed at $14.1, representing a decline of 1.5% from the previous closing price of $14.3. Overall, the financial results of CATALYST PHARMACEUTICALS for Q2 FY2023 show positive growth across several key metrics compared to the same period last year. The company is well placed for continued growth in the coming quarters and years. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Catalyst Pharmaceuticals. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Catalyst Pharmaceuticals. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Catalyst Pharmaceuticals. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Catalyst Pharmaceuticals are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – Catalyst Pharmaceuticals Intrinsic Stock Value
At GoodWhale, we believe that analyzing a company’s financials is essential for accurately assessing its value. One of the companies that we have recently analyzed is CATALYST PHARMACEUTICALS. Through our proprietary Valuation Line, we have determined that the intrinsic value of CATALYST PHARMACEUTICALS’s share is around $13.9. This is a reflection of the company’s current and future prospects based on our detailed assessment of their financial data. At the time of this analysis, CATALYST PHARMACEUTICALS stock was trading at $14.1, a fair price that is slightly overvalued by 1.7%. This suggests that there is some potential upside but that investors should be aware of the risk associated with investing in CATALYST PHARMACEUTICALS at this time. More…
Risk Rating Analysis
Star Chart Analysis
The pharmaceutical industry is intensely competitive, with companies vying for market share of both existing drugs and new drugs under development. Catalyst Pharmaceuticals Inc is no exception, competing against other pharmaceutical companies such as Gossamer Bio Inc, uniQure NV, and Spero Therapeutics Inc. In order to maintain or grow its market share, Catalyst must continually develop new and innovative drugs and market them effectively.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. The company’s market cap is $940.04M as of 2022 and its ROE is -672.28%. The company’s products include GB001, GB002 and GB004. GB001 is a phase 1 clinical trial product for the treatment of ulcerative colitis. GB002 is a phase 2 clinical trial product for the treatment of Crohn’s disease. GB004 is a phase 2 clinical trial product for the treatment of non-small cell lung cancer.
uniQure NV is a Dutch biotech company that focuses on the development and commercialization of gene therapies. As of 2022, the company has a market cap of 867.48M and a ROE of -12.84%. The company’s main products are Glybera and Amryt Pharma. Glybera is a gene therapy treatment for lipoprotein lipase deficiency, while Amryt Pharma is a treatment for epidermolysis bullosa.
– Spero Therapeutics Inc ($NASDAQ:SPRO)
Spero Therapeutics Inc is a pharmaceutical company that focuses on the development of treatments for rare and infectious diseases. The company has a market cap of $66.98 million and a return on equity of -138.12%. The company’s products include treatments for bacterial infections, fungal infections, and viral infections.
CATALYST PHARMACEUTICALS reported strong financial results for FY2023 Q2, with total revenue of USD 99.6 million, an increase of 87.5% year over year and net income of USD 37.8 million, up 74.7%. This provides a strong indicator of the potential of the company as an investment opportunity, as it continues to show consistent and healthy growth backed by increasing profits. With its strong performance in the quarter, CATALYST PHARMACEUTICALS is likely to be an attractive investment option for those looking to diversify their portfolio.